Login to Your Account



Abraxane's Deep 'MPACT'

Changing SOC: Will New Drugs Pan Out in Pancreatic Cancer?

By Jennifer Boggs
Managing Editor

Tuesday, February 19, 2013

NEW YORK – Last month's readout of Celgene Corp.'s successful Phase III study testing Abraxane (nab-paclitaxel) in combination with gemcitabine in pancreatic cancer is expected to change the standard of care for patients with metastatic disease, but its modest improvement in overall survival leaves plenty of room for new players in this notoriously difficult therapeutic space – assuming researchers can figure how to attack it.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription